UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine
ISSN 2079-0325(p)
DOI 10.36927/2079-0325
Home » Archive of numbers » 2022 » Volume 30, issue 2 (111) » THE PLACE OF GABAPENTINOIDS IN PROVIDING SPECIALIZED CARE TO PATIENTS WITH MENTAL AND BEHAVIORAL DISORDERS ACCORDING TO THE PRINCIPLES OF EVIDENCE-BASED MEDICINE (literature review)

THE PLACE OF GABAPENTINOIDS IN PROVIDING SPECIALIZED CARE TO PATIENTS WITH MENTAL AND BEHAVIORAL DISORDERS ACCORDING TO THE PRINCIPLES OF EVIDENCE-BASED MEDICINE (literature review)

Authors

Type of Article

  • Scientific Article

In the Section

  • LITERATURE REVIEW

Key words

Index UDK:
  • 616.89-008.447:615.213

Abstract

The article considers the problem of the use of gabapentinoids at the present stage to persons with mental and behavioral disorders according to the principles of evidence-based medicine based on the literature and the author’s own experience; the absence of a common opinion among the authors is determined; conclusions are drawn that the use of gabapentinoids to persons with mental and behavioral disorders are not for their intended purpose; the necessity of maintaining a balance between the potential benefits and the risk of harm and taking into account the high potential for the development of dependence on gabapentinoids in patients with different nosologies is emphasized, and therefore the appointment of gabapentinoids is not recommended for providing specialized care to patients as monotherapy, the question of the effectiveness of combination therapy remains open. The use of gabapentinoids is not recommended for providing specialized care for people with dependence on alcohol and other psychoactive substances, or with any other type of dependence. The features of the use of gabapentinoids in elderly patients and people with opioid dependence are determined.

Pages

  • 74-80

Year / Issue

Download PDF

References

  1. Mason B. J. Gabapentin for the treatment of alcoholuse disorder / B. J. Mason, S. Quello, F. Shadan // Expert Opinion on Investigational Drugs. 2018. Jan. 27(1). 113—124. DOI: https://doi.org/10.1080/13543784.2018.1417383.
  2. Effectiveness of gabapentin in reducing cravings and withdrawal in alcohol use disorder: a meta-analytic review / Ahmed S., Stanciu C. N., Kotapati P. V. [et al.] // Prim Care Companion CNS Disord. 2019. Aug 22. 21(4). 19r02465. DOI: https://doi.10.4088/PCC.19r02465.
  3. The role of gabapentin in the management of alcohol withdrawal and dependence / Jonathan G. Leung, Daniel HallFlavin, Sarah Nelson [et al.] // Ann Pharmacother. 2015. 49(8). 897—906. DOI: https://doi.10.1177/1060028015585849.
  4. Markozova L. M. Problema zastosuvannia habapentynoidiv v medychnii praktytsi. Materialy naukovo-praktychnoi konf. "Shchorichni terapevtychni chytannia. Neinfektsiini zakhvoriuvannia: profilaktyka ta zmitsnennia zdorov’ia v Ukraini", 22—23 kvitnia 2021 r., m. Kharkiv. S. 84
  5. Antiufieiev O. V. Zalezhnist vid prehabalinu — lirika, linbah, neohabin i habany. URL: https://renessans-center.com/uk/likuvannya-narkomaniji/zalezhnistvid-pregabalinu-neogabin-lirika-algerika-ta-gabana.
  6. Reports of gabapentin and pregabalin abuse, misuse, dependence, or overdose: An analysis of the Food And Drug Administration Adverse Events Reporting System (FAERS) / K. E. Evoy, J. R. Covvey, A. M., Peckham A. M. [et al.] // Res Social Adm Pharm. 2019 Aug. Vol. 15(8). P. 953—958. DOI: https://doi.org/10.1016/j.sapharm.2018.06.018.
  7. Mersfelder T. L. Gabapentin: Abuse, Dependence, and Withdrawal / T. L. Mersfelder, W. H. Nichols // Ann Pharmacother. 2016. 50(3). 229—233. DOI: https://doi.10.1177/1060028015620800.
  8. Deng H. Gabapentin dependence and withdrawal requiring an 18-month taper in a patient with alcohol use disorder: a case report / H. Deng, O. Benhamou, A. Lembke // Journal of Addictive Diseases. Oct-Dec 2021. 39(4). 575—578. DOI: https://doi.10.1080/10550887.2021.1907502
  9. Latest advice for medicines users. Drug Safety Update. MHRA: The monthly newsletter. Vol.  12, issue  9: April 2019: P. 9—10. URI: https://assets.publishing.service.gov.uk/government/uploads/system/uploads/attachment_data/file/795950/April-2019-PDF-final.pdf.
  10. Preuss C. V. Prescription of Controlled Substances: Benefits and Risks / C. V. Preuss, A. Kalava, K. C. King // In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2022 Jan. PMID: 30726003.
  11. Chincholkar M. Gabapentinoids: pharmacokinetics, pharmacodynamics and considerations for clinical practice / M. Chincholkar // British Journal of  2020. May, 14(2). 104—114. DOI: https://doi.10.1177/2049463720912496.
  12. Biological rationale and potential clinical use of gabapentin and pregabalin in bipolar disorder, insomnia and anxiety: protocol for a systematic review and meta-analysis / Houghton K. T., Forrest A., Awad A. [et al.] // BMJ Open. 2017. Mar 27; 7(3). e013433. DOI: https://doi.10.1136/bmjopen-2016-013433.
  13. A Systematic Review of the Clinical Use of Gabapentin and Pregabalin in Bipolar Disorder / Ng Q. X., Han M. X., Teoh S. E. [et al.] // Pharmaceuticals (Basel, Switzerland). 2021. Aug 24. 14(9). 834. DOI: https://doi.10.3390/ph14090834.
  14. Gabapentin for complex regional pain syndrome in Machado-Joseph disease: a case report / [Lo Y. C., Liao K. K., Lee Y. C., Soong B. W.] // J Med Case Rep. 2011 Jul 1; 5: 268. DOI: https://doi.org/10.1186/1752-1947-5-268.
  15. Complex Regional Pain Syndrome: A Comprehensive Review / Taylor, S. , Noor, N., Urits, I. [et al.]  // Pain Ther. 2021. Dec. 10(2). 875—892. DOI: https://doi.org/10.1007/s40122-021-00279-4.
  16. Frenette E. Restless legs syndrome in children: a review and update on pharmacological options / E. Frenette // Current Pharmaceutical Design. 2011. 17(15). 1436—42. DOI: https://doi.10.2174/138161211796197142.
  17. Pharmacotherapeutic management of sleep disorders in children with neurodevelopmental disorders / [Bruni O., Angriman M., Melegari M. G., Ferri R.] // Expert Opin Pharmacother. 2019. 22 Oct. 20(18). 2257—2271. DOI: https://doi.10.1080/14656566.2019.1674283.
  18. Gabapentin versus pregabalin in improving sleep quality and depression in hemodialysis patients with peripheral neuropathy: A randomized prospective crossover trial / Biyik Z., Solak Y., Atalay H. [et al.] // Int Urol Nephrol. 2013. Jun, 45(3). 831—837. DOI: https://doi.10.1007/s11255-012-0193-1.
  19. Basurto Ona X. Drug therapy for treating post‐dural puncture headache / Basurto Ona X., Osorio D., Cosp Bonfill // Cochrane Database Syst Rev. 2015. 7. 78—87. DOI: https://doi.10.1002/14651858.cd007887.pub3.
  20. Gabapentin or pregabalin for the prophylaxis of episodic migraine in adults /  [Linde M., Mulleners W.  , Chronicle E.  P., McCrory D.  C.]  // Cochrane Database Syst Rev. 2013. 6: CD010609. DOI: https://doi.10.1002/14651858.cd010609.
  21. Gabapentin for chronic neuropathic pain and fibromyalgia in adults / Moore R. A., Wiffen P. J., Derry S. [et al.] // Cochrane Database Syst Rev. 2014. Apr 27. CD007938. DOI: https://doi.10.1002/14651858.CD007938.pub3.
  22. Gabapentin add‐on treatment for drug‐resistant focal epilepsy / [Panebianco M., Al-Bachari S., Hutton J. L., Marson A. G.] // Cochrane Database Syst Rev. 2021. Jan 12. 1(1): CD001415. DOI: https://doi.10.1002/14651858.cd001415.pub4.
  23. Antiepileptic drug monotherapy for epilepsy: a network meta-analysis of individual participant data / Nevitt S. J., Sudell M., Cividini S. [et al.] // Cochrane Database Syst Rev. 2022. Apr 1; 4(4): CD011412. DOI: https://doi.10.1002/14651858.cd011412.pub4.
  24. Moore J. Gabapent in forchron i c n europathi c pain in adults / J.  Moore, C.  Gaines  // Br  J  Community Nurs. 2019. 24(12). 608—609. DOI: https://doi.10.12968/bjcn.2019.24.12.608.
  25. Garcia D. Gabapentin or Chronic Neuropathic Pain / D. Garcia  // Am  Fam  2015. 92(11). Online. PMID: 26760423.
  26. High-Dose Gabapentin for the Treatment of Severe Alcohol Withdrawal Syndrome: A Retrospective Cohort Analysis / Alexander R. Levine, Lorna Carrasquillo, Jane Mueller [et al.] // Pharmacotherapy. 2019 Sep; 39(9). 881—888. DOI: https://doi.0.1002/phar.2309.
  27. Gabapentin treatment for alcohol dependence: a randomized clinical trial / Barbara J. Mason, Susan Quello, Vivian Goodell [et al.] // JAMA Intern Med. 2014. 174(1). 70—7. DOI: https://doi.0.1001/jamainternmed.2013.11950.
  28. Efficacy of Gabapentin for the Treatment of Alcohol Use Disorder in Patients With Alcohol Withdrawal Symptoms: A Randomized Clinical Trial / Anton R. F., Latham P., Voronin K. [et  ]  // JAMA Intern Med. 2020. May  1; 180(5). 728—736. DOI: https://doi.10.1001/jamainternmed.2020.0249.
  29. Tiglao S. M. Alcohol Withdrawal Syndrome: Outpatient Management / S. M. Tiglao, E. S. Meisenheimer, R.   Oh.  // Am Fam Physician. 2021.104(3). 253—262. PMID: 34523874.
  30. Fixed-dose gabapentin augmentation in the treatment of alcohol withdrawal syndrome: a retrospective, open-label study / A. Andaluz, D. DeMoss, C. Claassen [et al.] // Am J Drug Alcohol Abuse. 2020. 46(1). 49—57. DOI: https://doi.10.1080/00952990.2019.1634085.
  31. Use of Gabapentin in the Treatment of Substance Use and Psychiatric Disorders: A Systematic Review / S. Ahmed, R. Bachu, P. Kotapati [et al.] // Front Psychiatry. 2019. May 7. 10:228. DOI: https://doi.10.3389/fpsyt.2019.00228.
  32. Medicines associated with dependence or withdrawal: a mixed-methods public health review and national database study in England / John Marsden, Martin White, Fizz Annand [et al.] // Lancet Psychiatry. 2019. Nov, 6(11), 935—950.DOI: https://doi.10.1016/S2215-0366(19)30331-1.
  33. Neuropathic pain in adults: pharmacological management in non-specialist settings: Clinical guideline [CG173]. Published: 20 November 2013. Last updated 22 September 2020. URI: https://www.nice.org.uk/guidance/cg173.
  34. Clinical Guidelines: Consensus on the Best Practices in Pain Medicine / The  American Academy of  Pain (AAMP). 2022. URI: https://painmed.org/clinical-guidelines/.
  35. Birse F. Moore Phenytoin for neuropathic pain and fibromyalgia in adults / F. Birse, S. Derry, R. Moor // Cochrane Database Syst Rev. 2012 May 16; 2012(5): CD009485. doi: https://doi.org/10.1002/14651858.CD009485.pub2.
  36. Mack A. Examination of the evidence for off-label use of gabapentin / A. Mack // J Manag Care Pharm. 2003 Nov; 9(6). 559—568. DOI: https://doi.org/10.18553/jmcp.2003.9.6.559.

Journal’s Indexing:

UKRAINS'KYI VISNYK PSYKHONEVROLOHII

The Scientific and Practical Journal of Medicine

ДУ «ІНПН імені
П.В. ВОЛОШИНА
НАМН УКРАЇНИ»